---
title: "MicuRx Pharmaceuticals signed a strategic cooperation agreement with Haiqing Pharmaceuticals"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/258381297.md"
description: "MicuRx Pharmaceuticals has signed a strategic cooperation agreement with Nanjing Haiqing Pharmaceuticals. The two parties will collaborate in areas such as market and customer network, and service value enhancement. The goal is to integrate market resources to promote the sales of the company's products in new regions and hospitals, with expected sales revenues of 260 million yuan, 388 million yuan, and 600 million yuan for the years 2026-2028, respectively. The two parties will also establish a product innovation cooperation platform, focusing on research in disease prevention and treatment, jointly developing new products, and promoting the internationalization of Chinese pharmaceutical companies"
datetime: "2025-09-22T14:20:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/258381297.md)
  - [en](https://longbridge.com/en/news/258381297.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/258381297.md)
---

# MicuRx Pharmaceuticals signed a strategic cooperation agreement with Haiqing Pharmaceuticals

According to the Zhitong Finance APP, MicuRx (688373.SH) announced that the company (Party A) signed a strategic cooperation agreement with Nanjing Haiqing Pharmaceutical Co., Ltd. (Party B) on September 22, 2025, in the Pudong New District of Shanghai, China. The agreement stipulates:

Through strategic cooperation, both parties will carry out close collaboration in areas such as market and customer networks, and service value enhancement. Both parties will combine the specific market conditions of each province, fully utilize the existing hospital markets and the extensive commercial channel resources accumulated by strategic investors over the years, and select strong partners with the highest promotion success rates for in-depth commercial promotion cooperation. Leveraging the partner's accumulation and influence in the antibacterial drug sales field, they will actively promote the access and volume increase of the company's products in new regions and hospital terminals. If the integration of the aforementioned market resources goes smoothly, the product sales revenue targets for 2026, 2027, and 2028 are set at 260 million yuan, 388 million yuan, and 600 million yuan, respectively.

Party B focuses on the development of active pharmaceutical ingredients and has accumulated extensive experience in the route development, process optimization, and production scaling of chemical active pharmaceutical ingredients. Party B will leverage its advantages in active pharmaceutical ingredient development and process development to reduce the company's product costs and enhance its profitability.

Both parties respond to the national "Healthy China 2030" strategy, relying on each other's high-quality resources and R&D experience to establish a product innovation cooperation platform, focusing on innovative research in disease prevention and treatment, further exploring the value of existing products and resources in therapeutic drugs, biological products, etc., jointly developing new products and services, achieving interactive product innovation, and further promoting Chinese pharmaceutical companies to go global.

Both parties will rely on existing overall resources to focus on advancing cooperation in the capital market, capital structure optimization, and fund utilization

### Related Stocks

- [688373.CN](https://longbridge.com/en/quote/688373.CN.md)

## Related News & Research

- [Dunkin' To Give Away 1 Mln Free Coffees For A Day](https://longbridge.com/en/news/286964019.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [10:30 ETInventHelp Inventor Develops New Line of Candies (SGM-681)](https://longbridge.com/en/news/286931125.md)
- [12:36 ETDiagnostics Direct LLC Wins Innovation Award from Johns Hopkins](https://longbridge.com/en/news/286945918.md)
- [10:00 ETHill's Pet Nutrition Announces 2026 Hill's Global Symposium - "Healthy Skin Starts From Within" - Exploring the Gut-Skin Axis](https://longbridge.com/en/news/286926460.md)